JPRN-jRCT2080224174已完成未知
A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran
Alnylam Pharmaceuticals, Inc. / Medpace Japan KK0 个研究点目标入组 211 人开始时间: 2018年12月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 211
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •Have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug
- •Be willing and able to comply with the protocol-required visit schedule and visit requirements and provide written informed consent
排除标准
- •Any new or uncontrolled condition that could make the patient unsuitable for participation
研究者
相似试验
进行中（未招募）
1 期
Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301EUCTR2012-003176-39-IEBiogen Idec Research Limited1,600
进行中（未招募）
1 期
Study to Evaluate the Long-term Safety and Efficacy of Patisiran (ALN-TTR02) in Patients with Familial Amyloidotic Polyneuropathy (FAP)Transthyretin mediated amyloidosis (ATTR)MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-003877-40-CYAlnylam Pharmaceuticals, Inc.228
进行中（未招募）
1 期
Study to Evaluate the Long-term Safety and Efficacy of Patisiran (ALN-TTR02) in Patients with Familial Amyloidotic Polyneuropathy (FAP)Transthyretin mediated amyloidosis (ATTR)MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-003877-40-ITALNYLAM PHARMACEUTICALS, INC.228
进行中（未招募）
1 期
Study to Evaluate the Long-term Safety and Efficacy of Patisiran (ALN-TTR02) in Patients with Familial Amyloidotic Polyneuropathy (FAP)Transthyretin mediated amyloidosis (ATTR)MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-003877-40-DEAlnylam Pharmaceuticals, Inc.228
进行中（未招募）
1 期
Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301Relapsing-remitting Multiple SclerosisMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-003176-39-CZBiogen Idec Research Limited1,600